◈ PeptideAtlasCONNECTED KNOWLEDGE
THE PEPTIDE REFERENCE

IGF-1 DES

IGF-1 DES is an experimental IGF-1 variant lacking the first three amino acids of the native hormone. It interacts less strongly with certain IGF-binding proteins, altering activity in laboratory systems. Cell and animal findings do not establish human muscle-building efficacy, a safe administration regimen, or regulatory approval.

Also known as des(1–3)IGF-I · Des IGF-1

Research / unapproved usePreclinical researchBones & muscles
AI-assisted source review · 2026-10-272 cited sources2 min read

At a glance

Sequence length67 amino acids
Structural changeFirst three IGF-1 residues removed
Research featureReduced interaction with some IGF-binding proteins
Evidence baseCell and animal experiments
US approvalNo approved IGF-1 DES product

Overview

Native IGF-1 has 70 amino acids and circulates in a tightly regulated system involving binding proteins. Removing its first three residues produces des(1–3)IGF-I, a research reagent used to study how those binding proteins modify growth-factor action. Greater potency in some cell assays reflects altered availability to receptors, rather than a universal multiplier of benefit in the human body. Animal studies have examined growth and protein balance in catabolic or renal-disease models. These are not controlled human performance trials. The compound is distinct from mecasermin, an approved recombinant human IGF-1 medicine with its own narrow indication and safety requirements.

Supporting sources [1] [2]

How it works

The truncated molecule can stimulate IGF receptor signaling while escaping some of the sequestration imposed by IGF-binding proteins. In experimental systems this changes effects on DNA synthesis, protein synthesis, and protein breakdown. The response depends on the binding proteins and receptors present in the model. Reduced binding-protein affinity should not be equated automatically with a predictable duration, tissue specificity, or therapeutic advantage in humans.

Supporting sources [1] [2]

What the cell studies show

Experiments comparing IGF molecules found that binding proteins inhibited native IGF-1 and IGF-2 more than des(1–3)IGF-I in the tested systems. This supports a mechanism for greater apparent potency where binding proteins limit exposure. It does not show preferential delivery to an injected muscle or a proven clinical anabolic effect.

Supporting sources [1]

Growth findings in a disease model

In rats with reduced renal mass, IGF-related treatments improved growth-related and nitrogen-balance measurements, with des(1–3)IGF-I affecting protein breakdown measures. The animals, illness, exposure, and endpoints differ substantially from healthy adults seeking muscle gain. Translation requires human pharmacology and controlled clinical outcomes, which these experiments do not provide.

Supporting sources [2]

Why a safe human profile cannot be assumed

IGF signaling affects metabolism and cell growth in multiple tissues. The cited experiments were not designed to determine human hypoglycemia risk, organ effects, or long-term tumor-related consequences. Those remain unresolved concerns rather than quantified risks for this analog. Research-product identity and sterility introduce further uncertainty beyond the molecule’s experimental biology.

Supporting sources [1] [2]

Is it an interchangeable version of mecasermin?

No. The missing residues deliberately change biological interactions, and the approved human IGF-1 product has a separate sequence, clinical program, and indication. A shared receptor pathway does not create therapeutic equivalence. No conclusion about safe human use of IGF-1 DES can be drawn solely from approval of another IGF medicine.

Supporting sources [1]

Reading this profile

Jurisdiction: United States: research analog with no FDA-approved therapeutic product.. Molecular class: Truncated 67-amino-acid insulin-like growth factor I analog.

This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.

Sources & references

Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.

  1. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. ↗
    Original research · Checked 2026-10-27
  2. IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. ↗
    Original research · Checked 2026-10-27
CONTINUE EXPLORING

Related profiles

Abaloparatide ↗Abaloparatide is a bone-forming prescription medicine for adults with osteoporosis at high fracture risk. It activates the parathyroid hormone type 1 receptor. Its strongest fracture-prevention evidence is in postmenopausal women; the indication in men is supported by increased bone mineral density.IGF-1 LR3 ↗IGF-1 LR3 is a laboratory growth-factor analog with an N-terminal extension and an arginine substitution. These modifications reduce binding to certain IGF-binding proteins and alter biological potency. Human therapeutic benefit is not established, and animal research raises concern that growth stimulation can also accelerate tumor growth.Mecasermin ↗Mecasermin is an approved IGF-1 replacement medicine for specific severe pediatric growth disorders. It is not interchangeable with growth hormone and is not an approved bodybuilding or anti-aging therapy; hypoglycemia, tissue overgrowth and malignancy-related precautions are central to its use.Mechano growth factor ↗Mechano growth factor refers to an IGF-1 splice-variant concept and, in many products, a synthetic E-domain fragment. Laboratory studies of that fragment have conflicting results. Exercise-related gene expression is not evidence that injecting MGF or PEG-MGF improves human muscle repair, strength, or recovery.Somapacitan ↗Somapacitan is a long-acting growth-hormone analog used for adult GH deficiency and specified pediatric growth disorders. Current U.S. labeling extends beyond pediatric GH deficiency to selected small-for-gestational-age, Noonan syndrome and idiopathic short-stature populations from age two and a half.Somatropin (rhGH) ↗Somatropin is recombinant human growth hormone with established, product-specific indications in GH deficiency and selected growth or wasting conditions. It is not an approved general anti-aging treatment, and excess exposure can cause metabolic, fluid-retention and growth-related complications.